On Tuesday, Shares of Viacom, Inc. (NASDAQ:VIAB), gained 1.57% to $44.02.
Viacom Inc., declared that on Thursday, November 12, 2015, it will issue financial results for the quarter and fiscal year ending September 30, 2015. The Company will conduct a conference call at 8:30 a.m. (ET), following the release of its earnings declaration.
Viacom Inc. operates as an entertainment content company in the United States and internationally. The company creates television programs, motion pictures, short-form video, applications, games, consumer products, social media, and other entertainment content. It operates in two segments, Media Networks and Filmed Entertainment.
Shares of Magnum Hunter Resources Corp (NYSE:MHR), inclined 4.29% to $0.730, during its last trading session.
Magnum Hunter Resources Corporation declared that it has declared a monthly cash dividend on the Company’s 10.25% Series C Cumulative Perpetual Preferred Stock, a monthly cash dividend on the Company’s 8.0% Series D Cumulative Preferred Stock and a monthly cash dividend on the Company’s 8.0% Series E Cumulative Convertible Preferred Stock. The outstanding shares of Series E Preferred Stock are represented by depositary shares, each representing a 1/1,000th interest of a share of Series E Preferred Stock.
The dividend on the Series C Preferred Stock, which is for the month of September 2015, is payable on September 30, 2015, to holders of record at the close of business on September 15, 2015. The payment will be an annualized 10.25% per share, which is equivalent to about $0.2135 per share, based on the $25.00 per share liquidation preference of the Series C Preferred Stock. The Series C Preferred Stock is presently listed on the NYSE MKT and trades under the ticker symbol “MHR.PRC”.
Magnum Hunter Resources Corporation, an independent oil and gas company, explores for, exploits, acquires, develops, and produces crude oil, natural gas, and natural gas liquid resources in the United States.
Finally, Baxalta Inc (NYSE:BXLT), ended its last trade with -2.33% loss, and closed at $35.24.
Novimmune SA, declared that it has signed an international research partnership agreement with Baxalta Incorporated (Baxalta) to develop novel bispecific antibodies for an unspecified indication. Financial terms of the deal were not revealed.
This is the first partnership utilizing Novimmune’s new kappa-lambda bispecific antibody technology. The proprietary platform generates fully human antibodies, which target two specific binding sites with one antibody.
“The kappa-lambda platform is exactly the right technology for therapy areas which need a bispecific antibody that is as close to a natural human antibody as you can get,” said Novimmune CEO Jack Barbut.
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, counting hemophilia A, hemophilia B, attained hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
